Trial reportDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2015
[Immunotherapy of uveal melanoma: vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma].
Trial report in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A non-commercial, multicenter, randomized, two-armed, open-label phase iii study to evaluate the adjuvant vaccination with tumor rna-loaded autologous dendritic cells versus observation of patients with resected monosomy 3 uveal melanoma
Phase I Vaccination Trial in Metastatic Uveal Melanoma Using IKKb-matured Dendritic Cells Loaded With Autologous Tumor-RNA + RNA Coding for Defined Antigens and Driver Mutations
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- mRNA vaccines in cancer immunotherapy: current progress and perspectives in solid tumors and hematologic malignancies.MedScience · 2026Review
- Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy.Journal for immunotherapy of cancer · 2024Article
- Dendritic cells as orchestrators of anticancer immunity and immunotherapy.Nature reviews. Clinical oncology · 2024Review
- Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response.British journal of cancer · 2023Review
- A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma.Frontiers in immunology · 2022Article
- Article
- Article
- [Uveal melanoma : Early detection as the key to successful personalized medicine].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020Review
- Blood Eosinophilia is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA.Pharmaceutics · 2020Article
- The Role of Immune Checkpoint Blockade in Uveal Melanoma.International journal of molecular sciences · 2020Review
- Clinicopathological and prognostic significance and molecular mechanisms governing uveal melanoma.Therapeutic advances in medical oncology · 2020Review
- Review
- [New treatment options for iridociliary tumors].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2019Review
- [New molecular pathological strategies for malignant iris tumors].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2019Review
- Characterization of CD4+ T cells primed and boosted by MHCII primary uveal melanoma cell-based vaccines.Oncotarget · 2019Article
- Uveal melanoma: relatively rare but deadly cancer.Eye (London, England) · 2017Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveal melanomas are the most common malignant tumors of the eye. With modern molecular biological diagnostic methods, such as chromosome 3 typing and gene expression analysis, these tumors can be categorized into highly aggressive (monosomy 3, class II) and less aggressive forms. This molecular biological stratification is primarily important for determining the risk of these tumors as no therapy is currently available that is able to prevent or delay metastases. A randomized study of patients with a poor prognosis (monosomy 3) is currently being carried out in order to determine whether a cancer vaccine prepared from autologous (patient's own) dendritic cells and uveal melanoma RNA can prevent or delay progression and further metastases of this extremely aggressive form of cancer. Inclusion in the uveal melanoma study, which hopes to provide a potential therapeutic option for patients, is only possible if patients are referred to an institution that is able to manufacture and provide this vaccination before the patient is operated on or treated with radiation. Untreated tumor material is necessary for producing the vaccine on an individualized patient basis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.